Home
About Us
Who we are
Founders and Chairs
Individual Members
Emeritus Members
Corporate and Research Members
Cambridge Angels Team
Infographic
Entrepreneurs
Why Cambridge Angels?
Is Angel Investing right for you?
Investment Criteria
Application Process
Apply
Angels
Membership Information
Member portal
Angel Interviews
Portfolio
Current Portfolio
Exits
Cambridge Angels Founded Companies
Portfolio facts
Portfolio Interviews
Apply to Cambridge Angels
News
Portfolio News
Ecosystem News

Welcome to the Cambridge Angels

Home
About Us
Who we are
Founders and Chairs
Individual Members
Emeritus Members
Corporate and Research Members
Cambridge Angels Team
Infographic
Entrepreneurs
Why Cambridge Angels?
Is Angel Investing right for you?
Investment Criteria
Application Process
Apply
Angels
Membership Information
Member portal
Angel Interviews
Portfolio
Current Portfolio
Exits
Cambridge Angels Founded Companies
Portfolio facts
Portfolio Interviews
Apply to Cambridge Angels
News
Portfolio News
Ecosystem News
Obesity treatment and the rise of the GLP-1 agonist
11 September 2023
Emmi Nicholl
Obesity treatment and the rise of the GLP-1 agonist
Emmi Nicholl
11 September 2023

Obesity treatment and the rise of the GLP-1 agonist

Emmi Nicholl
11 September 2023

Source:https://www.laingbuissonnews.com/healthcare-markets-content/infocus/obesity-treatment-and-the-rise-of-the-glp-1-agonist/

Newer PostNHS Innovation Accelerator opens for applications
Older PostCo-founder and CEO of @StartCodon Jason Mellad on helping healthcare start-ups thrive and why inclusion and diversity will change the world.
LI-In-Bug_small.png
Back to Top
Privacy
info@cambridgeangels.net